Female tumor marker test package

Cancer screening package detecting the most frequently occuring women’s tumor markers available for laboratory tests

Book an appointment

Tumor markers are produced by tumor cells. Our laboratory determines the concentration of proteins that may indicate some type of cancer. The increase and change in the levels of the tumor marker can be used primarily in the monitoring of the treatment of confirmed tumor patients, and in the follow-up of the possible clinical progression of the tumor. The screening test package examines tumor markers, the occurrence of which tumors may affect women more often. Our package contains the following tests for the most basic tumor markers, in which case the increased levels may raise the suspicion of changes in the liver, colon, pancreas, ovary, breast, lungs: AFP (liver, ovarian cancer), LDH (melanoma), CEA (tumors of colon, rectum, stomach, liver, pancreas, lung, breast, ovary), CA 125 (tumors of ovary, endometrium, pancreas, liver), HE4 (ovary, lung cancer ), NSE (lung, pancreas, thyroid tumors, neuroblastoma), ROMA index (ovarian cancer), CA 19-9 (pancreatic cancer), HCG (pancreatic, ovarian, breast tumors), CA 15-3 (breast cancer). A positive value does not necessarily mean cancer, but in this case, see your doctor to find out the reason for the increase in the marker level. A negative result does not completely rule out the presence of a tumor. The evaluation of the results and the establishment of a diagnosis are the responsibility of your treating physician.

LDH, AFP, CEA, HCG, CA 15-3, CA 125, HE4, CA-19-9, NSE, ROMA index

The Female tumor marker test package examines tumor markers that may indicate cancer that occurs primarily in women. Examining tumor marker levels is recommended mainly for monitoring the treatment of confirmed tumor patients and for following up the possible clinical progression of the tumor, but an abnormal level calls attention to a more thorough investigation. In case of deviation in marker concentrations, it is recommended to monitor the markers every one to two months.